Logo image of SPRB

SPRUCE BIOSCIENCES INC (SPRB) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:SPRB - US85209E2081 - Common Stock

85.74 USD
+1.74 (+2.07%)
Last: 12/26/2025, 8:16:47 PM
Fundamental Rating

1

We assign a fundamental rating of 1 out of 10 to SPRB. SPRB was compared to 530 industry peers in the Biotechnology industry. The financial health of SPRB is average, but there are quite some concerns on its profitability. SPRB is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year SPRB has reported negative net income.
In the past year SPRB has reported a negative cash flow from operations.
SPRB had negative earnings in each of the past 5 years.
SPRB had a negative operating cash flow in each of the past 5 years.
SPRB Yearly Net Income VS EBIT VS OCF VS FCFSPRB Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M -40M -50M

1.2 Ratios

SPRB has a worse Return On Assets (-312.67%) than 94.15% of its industry peers.
SPRB has a Return On Equity of -888.95%. This is amonst the worse of the industry: SPRB underperforms 80.00% of its industry peers.
Industry RankSector Rank
ROA -312.67%
ROE -888.95%
ROIC N/A
ROA(3y)-72.45%
ROA(5y)-53.79%
ROE(3y)-104.69%
ROE(5y)-74.36%
ROIC(3y)N/A
ROIC(5y)N/A
SPRB Yearly ROA, ROE, ROICSPRB Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 0 -1K -2K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for SPRB so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
SPRB Yearly Profit, Operating, Gross MarginsSPRB Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 -200 -400 -600 -800 -1K

More info and screens

4

2. Health

2.1 Basic Checks

SPRB does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for SPRB has been increased compared to 1 year ago.
The number of shares outstanding for SPRB has been increased compared to 5 years ago.
SPRB has a worse debt/assets ratio than last year.
SPRB Yearly Shares OutstandingSPRB Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 100K 200K 300K 400K 500K
SPRB Yearly Total Debt VS Total AssetsSPRB Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

2.2 Solvency

SPRB has an Altman-Z score of -29.89. This is a bad value and indicates that SPRB is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of -29.89, SPRB is not doing good in the industry: 88.87% of the companies in the same industry are doing better.
There is no outstanding debt for SPRB. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -29.89
ROIC/WACCN/A
WACC8.73%
SPRB Yearly LT Debt VS Equity VS FCFSPRB Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M

2.3 Liquidity

A Current Ratio of 1.54 indicates that SPRB should not have too much problems paying its short term obligations.
SPRB has a Current ratio of 1.54. This is amonst the worse of the industry: SPRB underperforms 82.08% of its industry peers.
A Quick Ratio of 1.54 indicates that SPRB should not have too much problems paying its short term obligations.
SPRB has a worse Quick ratio (1.54) than 81.13% of its industry peers.
Industry RankSector Rank
Current Ratio 1.54
Quick Ratio 1.54
SPRB Yearly Current Assets VS Current LiabilitesSPRB Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

More info and screens

1

3. Growth

3.1 Past

The earnings per share for SPRB have decreased strongly by -19.06% in the last year.
SPRB shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -90.18%.
EPS 1Y (TTM)-19.06%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%7.43%
Revenue 1Y (TTM)-90.18%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-100%

3.2 Future

Based on estimates for the next years, SPRB will show a quite strong growth in Earnings Per Share. The EPS will grow by 14.85% on average per year.
SPRB is expected to show a very negative growth in Revenue. In the coming years, the Revenue will decrease by -14.87% yearly.
EPS Next Y85.84%
EPS Next 2Y39.87%
EPS Next 3Y15.69%
EPS Next 5Y14.85%
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y25.64%
Revenue Next 5Y-14.87%

3.3 Evolution

SPRB Yearly Revenue VS EstimatesSPRB Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2023 2024 2027 2028 2030 2031 2032 50M 100M
SPRB Yearly EPS VS EstimatesSPRB Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -100 -200 -300

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for SPRB. In the last year negative earnings were reported.
Also next year SPRB is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SPRB Price Earnings VS Forward Price EarningsSPRB Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SPRB Per share dataSPRB EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -20 -40 -60 -80

4.3 Compensation for Growth

A more expensive valuation may be justified as SPRB's earnings are expected to grow with 15.69% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y39.87%
EPS Next 3Y15.69%

More info and screens

0

5. Dividend

5.1 Amount

SPRB does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

SPRUCE BIOSCIENCES INC

NASDAQ:SPRB (12/26/2025, 8:16:47 PM)

85.74

+1.74 (+2.07%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-10 2025-11-10/amc
Earnings (Next)04-13 2026-04-13/amc
Inst Owners41.05%
Inst Owner Change-41.49%
Ins Owners8.02%
Ins Owner Change0.16%
Market Cap91.74M
Revenue(TTM)697.00K
Net Income(TTM)-47.88M
Analysts80
Price Target213.69 (149.23%)
Short Float %10.41%
Short Ratio0.14
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)39.74%
Min EPS beat(2)-2.58%
Max EPS beat(2)82.06%
EPS beat(4)1
Avg EPS beat(4)-33.2%
Min EPS beat(4)-166.11%
Max EPS beat(4)82.06%
EPS beat(8)5
Avg EPS beat(8)-5.32%
EPS beat(12)8
Avg EPS beat(12)-0.08%
EPS beat(16)11
Avg EPS beat(16)2.38%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)55.76%
PT rev (3m)13866.7%
EPS NQ rev (1m)2.69%
EPS NQ rev (3m)-3885.67%
EPS NY rev (1m)39.48%
EPS NY rev (3m)-2238.16%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)-100%
Revenue NY rev (1m)N/A
Revenue NY rev (3m)-100%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 131.62
P/FCF N/A
P/OCF N/A
P/B 17.03
P/tB 17.03
EV/EBITDA N/A
EPS(TTM)-84.83
EYN/A
EPS(NY)-4.19
Fwd EYN/A
FCF(TTM)-44.44
FCFYN/A
OCF(TTM)-44.44
OCFYN/A
SpS0.65
BVpS5.03
TBVpS5.03
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -312.67%
ROE -888.95%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-72.45%
ROA(5y)-53.79%
ROE(3y)-104.69%
ROE(5y)-74.36%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.05
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.54
Quick Ratio 1.54
Altman-Z -29.89
F-Score2
WACC8.73%
ROIC/WACCN/A
Cap/Depr(3y)8.1%
Cap/Depr(5y)65.57%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-19.06%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%7.43%
EPS Next Y85.84%
EPS Next 2Y39.87%
EPS Next 3Y15.69%
EPS Next 5Y14.85%
Revenue 1Y (TTM)-90.18%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-100%
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y25.64%
Revenue Next 5Y-14.87%
EBIT growth 1Y-14.44%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-114.46%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-40.63%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-40.67%
OCF growth 3YN/A
OCF growth 5YN/A

SPRUCE BIOSCIENCES INC / SPRB FAQ

Can you provide the ChartMill fundamental rating for SPRUCE BIOSCIENCES INC?

ChartMill assigns a fundamental rating of 1 / 10 to SPRB.


What is the valuation status for SPRB stock?

ChartMill assigns a valuation rating of 0 / 10 to SPRUCE BIOSCIENCES INC (SPRB). This can be considered as Overvalued.


What is the profitability of SPRB stock?

SPRUCE BIOSCIENCES INC (SPRB) has a profitability rating of 0 / 10.


How financially healthy is SPRUCE BIOSCIENCES INC?

The financial health rating of SPRUCE BIOSCIENCES INC (SPRB) is 4 / 10.


What is the expected EPS growth for SPRUCE BIOSCIENCES INC (SPRB) stock?

The Earnings per Share (EPS) of SPRUCE BIOSCIENCES INC (SPRB) is expected to grow by 85.84% in the next year.